Calpain in Atrial Fibrillation: Friend or Foe?

Editorial to: “Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model” by Yue Li et al.
  • Uwe Lendeckel
  • Andreas Goette

Key words

Apoptosis Fibrillation Calcium Calpain 

Atrial fibrillation (AF) is associated with the occurrence of substantial structural changes in atrial tissue. AF is known to induce a cellular calcium-overload due to an increased influx of calcium through L-type calcium channels. Therefore, alterations of intracellular calcium homeostasis with activation of calcium-dependent signalling pathways like calcineurin and calpain appear of particular importance. Whereas calcineurin-dependent signalling contributes to the development of atrial hypertrophy [1, 2, 3], activation of the calcium-dependent protease calpain I may lead to destruction of cellular proteins. The histopathology of fibrillating atria is thought to be similar to chronically ischemic ventricular myocardium. A study by Goette et al. [4] showed that patients with AF have increased expression and activity of calpain I in atrial tissue. The changes in calpain activity were accompanied by reduced amounts of TnT and morphological degradation of myofilaments in fibrillating atria. Aime-Sempe et al. [5] provided evidence of an increased rate of apoptosis in fibrillating human atria. Importantly, inflammatory infiltrates were not observed in that study either. This suggests that non-inflammatory pathways contribute for the described apoptotic cell death in atrial tissue.

The present study by Yue Li et al. [6] shows that an inhibitor of calpain I (N-Acetyl-Leu-Leu-Met; ALLM) diminishes the extent of apoptotic cell death in an in vivo canine model of AF. They show that inhibition of calpain I is able to reduce the rate of apoptosis (apoptosis index) and caspase expression as otherwise found highly increased after the 3 week period of atrial pacing. Anti-apoptotic proteins like bcl2 recovered by ALLM therapy are indicative of calpain activity being upstream of mitochondrial apoptotic pathways. Thus, the present paper provides first evidence using an in vivo model that inhibition of calpain I prevents pacing- induced apoptosis. This finding may have important implications since increased rate of apoptosis might affect the electrical and mechanical properties of fibrillating atrial tissue. Nevertheless, it still has to be proven that the demonstrated molecular effects of ALLM influence directly the occurrence/persistence of AF or the mechanical atrial function. Thus, it appears too early to state that ALLM is useful as upstream therapy in AF.

Calpain I cleaves a variety of proteins to promote apoptosis with caspase-7 being just one recent example [7]. However, there is apparent crosstalk between apoptotic and necrotic pathways and activation of calpain promotes apoptosis even during caspase inhibition. In the heart, caspase-independent induction of apoptosis has been recently shown to occur via release of apoptosis-inducing factor (AIF) from mitochondria [8], which in other tissues was shown to be mediated by elevated intracellular Ca2+-levels [9] or calpain I [10].

Interestingly, the results of the present study are supported by data from previous studies obtained ex vivo. Rapid ex vivo stimulation of HL-1 atrial myocytes showed reduced expression of L-type Ca2+-channel alpha 1C subunits by -72%. The pacing-induced reduction of L-type Ca2+-channel protein was fully prevented by treatment with verapamil, the active stereoisomer of methoxyverapamil D600, the calpain inhibitors PD150606 and E64d, and LaCl(3). Interestingly, PD150606, E64d and LaCl(3), but not verapamil, prevented structural changes. Swelling and disruption of mitochondria are typical morphologic findings in fibrillating atrial tissue [11]. Mitochondrial dysfunction and concomitant opening of the permeability transition pore is strongly correlated with cell death [12], and interventions to prevent pore opening have been shown to protect the myocardium [13]. AF has been shown to cause severe damage of mitochondrial structure and to provoke mitochondrial dysfunction, which is in part due to the frequency-dependent intracellular Ca2+-overload [14, 15]. Accordingly, verapamil was shown to preserve mitochondrial structure and function [14, 15]. The critical requirement for mitochondrial participation in the death process is underscored by the protective effect of the mitochondrial ATP-sensitive potassium channel in preconditioning. This channel has been suggested to preserve calcium homeostasis and would therefore limit calpain activation [16]. Indeed, calpain inhibition was protective in models of ischemia/reperfusion which suggests that pore opening, if it occurs, is downstream of calpain activation [17]. The study of Yue Li et al. implies that similar mechanisms apply during AF. However, the role of apoptosis in cardiac disease and especially in AF remains unclear. Apoptosis is a consistent finding in many cardiovascular diseases. According to Lockshin et al. [18], myocyte apoptosis may reflect extensive damage to cardiac tissue rather than causing it. If so, preventing apoptosis would lead cells into necrotic death, which may be even more harmful. Preventing apoptosis appears to be beneficial in acute situations such as myocardial infarction. In more chronic situations like persistent AF apoptosis may facilitate “sterile and silent” removal of irreversibly damaged cells. Therefore, a true possible benefit of calpain-inhibitor administration in AF remains to be elucidated in future studies.


  1. 1.
    Qi XY, Yeh YH, Xiao L, et al. Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current. Circ Res. 2008;103:845–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215–28.CrossRefPubMedGoogle Scholar
  3. 3.
    Bukowska A, Lendeckel U, Hirte D, et al. Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. Cell Mol Life Sci. 2006;63:333–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Goette A, Arndt M, Röcken C, et al. Calpains and cytokines in fibrillating human atria. Am J Physiol Heart Circ Physiol. 2002;283:H264–72.PubMedGoogle Scholar
  5. 5.
    Aimé-Sempé C, Folliguet T, Rücker-Martin C, et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol. 1999;34:1577–86.CrossRefPubMedGoogle Scholar
  6. 6.
    Li Y, Gong Z, Xue H, et al. Anti-apoptotic effects of a calpain inhibitor on cardiomyocytes in a canine rapid atrial fibrillation model. Cardiovasc Drug Ther. 2009;23: this issue.Google Scholar
  7. 7.
    Gafni J, Cong X, Chen SF, Gibson BW, Ellerby LM. Calpain-1 cleaves and activates caspase-7. J Biol Chem. 2009; 284: 25441–9.Google Scholar
  8. 8.
    Choudhury S, Bae S, Kumar SR, et al. Role of AIF in cardiac apoptosis in hypertrophic cardiomyocytes from Dahl salt sensitive rats. Cardiovasc Res. 2009, Aug 14, [Epub ahead of print].Google Scholar
  9. 9.
    Norberg E, Gogvadze V, Ott M, et al. An increase in intracellular Ca2+ is required for the activation of mitochondrial calpain to release AIF during cell death. Cell Death Differ. 2008;15:1857–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Cao G, Xing J, Xiao X, et al. Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in ischemic neuronal injury. J Neurosci. 2007;27:9278–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Brundel BJ, Kampinga HH, Henning RH. Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation. Cardiovasc Res. 2004;62:521–52.CrossRefPubMedGoogle Scholar
  12. 12.
    Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J. 1999;341:233–49.CrossRefPubMedGoogle Scholar
  13. 13.
    Di Lisa F, Menabò R, Canton M, Barile M, Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem. 2001;276:2571–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Bukowska A, Schild L, Keilhoff G, Hirte D, et al. Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia. Exp Biol Med (Maywood). 2008;233:558–74.CrossRefGoogle Scholar
  15. 15.
    Schild L, Bukowska A, Gardemann A, et al. Rapid pacing of embryoid bodies impairs mitochondrial ATP synthesis by a calcium-dependent mechanism–a model of in vitro differentiated cardiomyocytes to study molecular effects of tachycardia. Biochim Biophys Acta. 2006;1762:608–15.PubMedGoogle Scholar
  16. 16.
    Murata M, Akao M, O’Rourke B, Marbán E. Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res. 2001;89:891–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Chen M, Won DJ, Krajewski S, Gottlieb RA. Calpain and mitochondria in ischemia/reperfusion injury. J Biol Chem. 2002;277:29181–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Lockshin RA, Facey CO, Zakeri Z. Cell death in the heart. Cardiol Clin. 2001;19:1–11.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Institute of Medical Biochemistry and Molecular BiologyErnst-Moritz-Arndt UniversityGreifswaldGermany
  2. 2.Division of Cardiology, University HospitalOtto-von-Guericke UniversityMagdeburgGermany
  3. 3.Department of Internal Medicine, Division of CardiologyUniversity Hospital MagdeburgMagdeburgGermany

Personalised recommendations